1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base, and Forecast Years Timeline
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Sources
2.3. Research Design
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET, BY TYPE OF NEUROGENERATIVE DISEASE
5.1. Introduction
5.2. Alzheimer's Disease
5.3. Parkinson's Disease
5.4. Huntington's Disease
5.5. Amyotrophic Lateral Sclerosis (ALS)
5.6. Multiple System Atrophy (MSA)
5.7. Spinocerebellar Ataxias
5.8. Others
6. GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET, BY THERAPEUTIC APPROACH
6.1. Introduction
6.2. Gene Replacement Therapy
6.3. Gene Silencing Therapy (RNAi)
6.4. Gene Editing Therapy (CRISPR-Cas9)
6.5. Neurotrophic Factor Delivery
6.6. Enzyme Replacement Therapy
7. GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET, BY VECTOR TYPE
7.1. Introduction
7.2. Adeno-Associated Virus (AAV)
7.3. Lentivirus
7.4. Retrovirus
7.5. Non-Viral Vectors
8. GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET BY END-USER
8.1. Introduction
8.2. Hospitals and Clinics
8.3. Research Institutions
8.4. Biotechnology Companies
8.5. Pharmaceutical Companies
9. GENE THERAPY FOR NEURODEGENERATIVE DISEASES MARKET, BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. United States
9.2.2. Canada
9.2.3. Mexico
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Others
9.4. Europe
9.4.1. United Kingdom
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Others
9.5. Middle East and Africa
9.5.1. Saudi Arabia
9.5.2. UAE
9.5.3. Others
9.6. Asia Pacific
9.6.1. Japan
9.6.2. China
9.6.3. India
9.6.4. South Korea
9.6.5. Indonesia
9.6.6. Taiwan
9.6.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
10.1. Major Players and Strategy Analysis
10.2. Emerging Players and Market Lucrativeness
10.3. Mergers, Acquisitions, Agreements, and Collaborations
10.4. Vendor Competitiveness Matrix
11. COMPANY PROFILES
11.1. Voyager Therapeutics
11.2. uniQure N.V.
11.3. Axovant Gene Therapies
11.4. Novartis AG
11.5. Amicus Therapeutics
11.6. REGENXBIO Inc.
11.7. Sarepta Therapeutics
11.8. GenSight Biologics
11.9. Krystal Biotech
11.10. Avexis (Acquired by Novartis)